BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11950487)

  • 1. Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study.
    Del Gadillo JC; Siebzehnrübl E; Dittrich R; Wildt L; Lang N
    Eur J Obstet Gynecol Reprod Biol; 2002 May; 102(2):179-83. PubMed ID: 11950487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
    Itskovitz-Eldor J; Kol S; Mannaerts B
    Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients.
    Moraloglu O; Kilic S; Karayalçin R; Yuksel B; Tasdemir N; Işik A; Ugur M
    Adv Ther; 2008 Mar; 25(3):266-73. PubMed ID: 18345521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of GnRh antagonist (Cetrorelix) in controlled ovarian hyperstimulation in women with polycystic ovary disease].
    Kdous M; M'Solly S; Zhioua F; Meriah S
    Tunis Med; 2008 Dec; 86(12):1060-5. PubMed ID: 19213514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
    Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH.
    Levi-Setti PE; Cavagna M; Bulletti C
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):212-6. PubMed ID: 16377062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the GnRH Antagonist Protocol Effective at Preventing OHSS for Potentially High Responders Undergoing IVF/ICSI?
    Xing W; Lin H; Li Y; Yang D; Wang W; Zhang Q
    PLoS One; 2015; 10(10):e0140286. PubMed ID: 26468951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
    Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
    Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin-releasing hormone agonist short regimen on alternate days and an antagonist protocol for assisted fertilization treatments.
    Maldonado LG; Franco JG; Setti AS; Iaconelli A; Borges E
    Fertil Steril; 2013 May; 99(6):1615-22. PubMed ID: 23394779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled ovarian stimulation using a long gonadotropin-releasing hormone antagonist protocol: a proof of concept and feasibility study.
    Weissman A; Ravhon A; Steinfeld Z; Nahum H; Golan A; Levran D
    Gynecol Obstet Invest; 2013; 76(2):113-8. PubMed ID: 23920048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
    Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
    Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cetrotide confirmatory trial of cetrorelix/0.25 mg in 26 women undergoing ovarian stimulation with recombinant follicle stimulating hormones for IVF, ICSI and embryo transfer (ET).
    Mettler L; Brandenburg K
    Clin Exp Obstet Gynecol; 2000; 27(2):103-5. PubMed ID: 10968345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Ratios Between Prognostic Factors Predict the Clinical Pregnancy Rate in an IVF/ICSI Program with a GnRH Agonist-FSH/hMG Protocol? An Assessment of 2421 Embryo Transfers, and a Review of the Literature.
    Merviel P; Menard M; Cabry R; Scheffler F; Lourdel E; Le Martelot MT; Roche S; Chabaud JJ; Copin H; Drapier H; Benkhalifa M; Beauvillard D
    Reprod Sci; 2021 Feb; 28(2):495-509. PubMed ID: 32886340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.